KMT2E and neoplasm: Ligands for NKp44 have been identified during pathological conditions such as tumor development or immortalized cell lines of cancerous origin, and include an isoform of the protein MLL5, proliferating cell nuclear antigen (PCNA), and platelet derived growth factor (PDGF)-DD (5, 68, 69).